Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boston Scientific enrols first patient in Lotus Valve System trial

Boston Scientific enrols first patient in Lotus Valve System trial

15th October 2012

Boston Scientific has announced the first patient enrolment for a new study assessing the safety and efficacy of its innovative Lotus Valve System.

The Reprise II trial will assess the performance of the device among up to 120 severe aortic valve disease patients, with 15 sites across Australia, France, Germany and the UK to be involved in the study.

Boston Scientific hopes to secure European CE Mark approval using data from this trial, following the acquisition of the technology as part of its Sadra Medical takeover last year.

The Lotus Valve System is the first transcatheter aortic valve replacement device of its kind and can minimise aortic regurgitation, as well as being fully repositionable and retrievable prior to release.

Dr Keith Dawkins, global chief medical officer for Boston Scientific, said: "We believe the Lotus Valve System is a unique technology that will offer interventional cardiologists greater precision and control in deployment which, in effect, may simplify the implantation procedure and lead to improved patient outcomes."

This comes after the company announced the acquisition of cardiac mapping and navigation solutions provider Rhythmia Medical last week.ADNFCR-8000103-ID-801469799-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.